TABLE 3.

Correlation between CBX7 expression and clinicopathologic characteristics of LUAD patients (n = 535).

Characteristic	Low expression of CBX7	High expression of CBX7	p
N	267	268
T stage, n (%)			<0.001
T1	63 (11.8%)	112 (21.1%)
T2	166 (31.2%)	123 (23.1%)
T3	24 (4.5%)	25 (4.7%)
T4	13 (2.4%)	6 (1.1%)
N stage, n (%)			0.001
N0	162 (31.2%)	186 (35.8%)
N1	47 (9.1%)	48 (9.2%)
N2	52 (10%)	22 (4.2%)
N3	1 (0.2%)	1 (0.2%)
M stage, n (%)			0.991
M0	194 (50.3%)	167 (43.3%)
M1	14 (3.6%)	11 (2.8%)
Pathologic stage, n (%)			0.004
Stage I	134 (25.4%)	160 (30.4%)
Stage II	61 (11.6%)	62 (11.8%)
Stage III	57 (10.8%)	27 (5.1%)
Stage IV	14 (2.7%)	12 (2.3%)
Gender, n (%)			0.052
Female	131 (24.5%)	155 (29%)
Male	136 (25.4%)	113 (21.1%)
Age, n (%)			0.005
≤65	145 (28.1%)	110 (21.3%)
>65	115 (22.3%)	146 (28.3%)
Smoker, n (%)			0.006
No	26 (5%)	49 (9.4%)
Yes	234 (44.9%)	212 (40.7%)
Age, meidan (IQR)	63 (57.75, 71)	67 (60, 74)	<0.001